Whipple disease is a chronic disease caused by Tropheryma whipplei [1] , a recently cultured bacteria. Invariably fatal before antibiotic treatment, it was empirically treated successively by tetracycline, penicillin G and streptomycin, and trimethoprim-sulfamethoxazole [2] . However, the rate of relapse or treatment failure is as high as 23% [1, 3] . The currently recommended antibiotic treatment is trimethoprim (160 mg) and sulfamethoxazole (800 mg) administered orally twice per day for 1 or 2 years, which is usually preceded by or initiated with parenteral delivery [3] . The literature is extremely confusing when trying to evaluate Whipple disease treatment. Primary failure should be differentiated from relapse after antibiotic cessation. A comprehensive study by Feurle and Marth [4] showed that patients initially presenting with a central nervous system infection are more likely to be cured with trimethoprimsulfamethoxazole than with doxycycline (2 of 8 patients). This study, which excluded patients whose initial diagnosis included central nervous system involvement, showed comparable failure rates in patients treated with doxycycline or trimethoprim-sulfamethoxazole (1 death in each group). However, long-term follow-up of patients with cerebral Whipple disease by Schnider et al. [5] revealed that 5 (42%) of 12 patients did not respond to trimethoprim-sulfamethoxazole. The authors concluded that trimethoprim-sulfamethoxazole did not prevent or cure central nervous system involvement in all patients with Whipple disease [5] . In a large study conducted by Durand et al. [6] , 1 (7%) of 15 patients treated with trimethoprim-sulfamethoxazole died, and in 2 patients doxycycline failed to improve gas-trointestinal symptoms. Overall, we identified 5 cases of failure with trimethoprim-sulfamethoxazole and found that 10%-15% of patients in reported series did not respond to trimethoprim-sulfamethoxazole [4, 6 -8] . Among these, 3 experienced apparent acquired resistance clinically [4, 8] .
The recent culture [9] and subsequent genome sequencing of T. whipplei [10, 11] made it possible to find that the target gene of trimethoprim, dihydrofolate reductase, is not present in the T. whipplei genome [12] . Furthermore, the genetic sequence that typically encodes dihydropteroate synthase (DHPS) and that serves as the target of sulfamethoxazole [13, 14] is not found as an individual open reading frame in the genome of T. whipplei. We previously tested various antibiotic compounds in vitro and found that T. whipplei was resistant to trimethoprim (confirming the genomic prediction) and susceptible to sulfamethoxazole at minimal inhibitory concentrations of 0.5-1 g/mL [14] . On the basis of these data, we concluded that current recommendations for Whipple disease involve monotherapy with sulfamethoxazole. We predicted that sulfamethoxazole resistance due to mutation in the gene encoding the enzyme putatively considered to be DHPS (hereafter, "putative DHPS") may occur during the treatment of this chronic disease.
Here, we report a case of trimethoprim-sulfamethoxazole treatment failure in a patient with Whipple disease. We identified a trifunctional enzyme that includes putative DHPS, and we found amino acid mutations, acquired during treatment, in the corresponding protein from an isolate recovered from the patient. Genotyping revealed that the strain recovered at the time of diagnosis was identical to the strain recovered at the time of treatment failure. Gene complementation analysis involving an Escherichia coli strain that lacked the gene encoding DHPS revealed that a copy of the putative DHPS gene recovered from a sulfamethoxazole-susceptible T. whipplei isolate restored the folate biosynthesis pathway and sulfamethoxazole susceptibility and that a mutated copy of the putative DHPS gene was associated with resistance to sulfamethoxazole.
PATIENT, MATERIALS, AND METHODS
Since our reports on the culture of T. whipplei, our center has become a reference center for Whipple disease [15] . We receive samples for diagnosis, are contacted by telephone or e-mail for treatment consultations, and receive patients for treatment and follow-up. We have diagnosed or confirmed 145 cases of Whipple disease and 28 cases of asymptomatic T. whipplei carriage (unpublished data) [16] . In 2002, on the basis of our in vitro findings [13, 14] , we began treating classic Whipple disease with doxycycline (200 mg daily) and hydroxychloroquine (600 mg daily), adding trimethoprim (960 mg daily) and sulfamethoxazole (4800 mg daily, which is 3 times the previously recommended dosage) to regimens for patients with neurological symptoms or polymerase chain reaction (PCR) detection of T. whipplei in cerebrospinal fluid. Some patients receiving the usual trimethoprim-sulfamethoxazole treatment have recently been referred to us because of primary treatment failure. Treatment was considered to have failed if a patient with a diagnosis of Whipple disease that was based on PCR and immunohistochemical staining for T. whipplei antibodies either had no clinical improvement or had clinical relapse (i.e., arthralgias, diarrhea, and weight loss) during treatment.
This work was approved by the local ethics committee. The patient provided informed consent.
Case Report
A 78-year-old man was admitted to the hospital in December 2005 with arthralgia, diarrhea, and weight loss. A diagnosis of Whipple disease was made in 2003 because of arthralgias, diarrhea, weight loss, ascitis, anemia, and periodic acid-Schiffstaining positive macrophages in duodenal biopsy specimens. He was treated with trimethoprim-sulfamethoxazole (320 mg and 1600 mg/day, respectively). Treatment resulted in significant clinical improvement, with the disappearance of diarrhea and arthralgia in 2 weeks and a weight gain of 6 kg. Duodenal biopsy and cerebrospinal fluid puncture were not performed during the initial follow-up visit, at which time the patient was still receiving trimethoprim-sulfamethoxazole. However, despite continued treatment, diarrhea, fever, and anemia reappeared 19 months after the initial presentation. Immunohistochemical staining of macrophages from duodenal biopsy specimen revealed T. whipplei (figure 1). PCR was performed as described elsewhere [1] , and T. whipplei was detected duodenal biopsy specimens, saliva, stool, blood, and cerebrospinal fluid. Treatment with doxycycline (200 mg/day) and hydroxychloroquine (200 mg 3 times/day) was started. Stool, saliva, and blood have been PCR negative since February 2006. Cerebrospinal fluid puncture was not performed during the follow-up period. The patient showed rapid improvement. By June 2007, his weight had increased by 9 kg, he felt well, and he was still receiving therapy.
Genotyping and Culture
Genotyping of T. whipplei DNA from the duodenal biopsy specimen obtained at the time of Whipple disease diagnosis and from the stool and duodenal biopsy specimens obtained at the time of clinical resistance was performed, as previously reported [17, 18] . This was done to confirm that the isolates had the same genotype. A culture of the stool specimen was attempted, as previously reported, when the patient consulted for clinical failure [16, 17] .
Identification of the Gene Encoding Putative DHPS, Sequencing of DNA from Patient Isolates, and Detection of Critical Amino Acid Mutations
We searched the Kyoto Encyclopedia of Genes and Genomes (KEGG) Web site (available at: http://www.genome.jp) for the gene encoding putative DHPS in the 2 available complete genome sequences of T. whipplei strain Twist (Genbank accession number NC_004572) and T. whipplei strain TW08/27 (Genbank accession number NC_004551). The search was conducting using the DBGET search tool and the following keywords: "dihydropteroate synthase" and "folP," which corresponds to the gene that encodes putative DHPS. Twenty T. whipplei strains from 20 patients were isolated and established in our laboratory as previously reported (17, 19 -21) , and one DNA sample obtained before and another after treatment failure from the case patient were used in this study (table 1) . These samples were screened by PCR followed by DNA sequencing using specific oligonucleotide primers of the candidate gene folP. Three sets of primers were designed according to the 2 available complete genome sequences of T. whipplei, to frame the gene encoding putative DHPS (table 2, which appears only in the electronic edition of the Journal). The nucleotide sequences and amino acid sequences of candidate genes were compared using the CLUSTAL W program (available at: http://www.ebi.ac.uk/clustalw/) to detect possible mutations that could be associated with sulfonamide resistance. The 3-dimensional structure of E. coli DHPS (Genbank accession number 1AJ0) was retrieved at the NCBI Structure Web site and used for amino acid numbering and 3-dimensional construction, using Cn3d software, version 4.1 (available at: http://www.ncbi.nlm.nih.gov/Structure/CN3D/ cn3d.shtml), to show the critical mutations that could be associated with sulfonamide resistance.
Amplification, Cloning, and Expression of dhps in E. coli Knockout Strains
E. coli strains, growth media, and transformation. E. coli One Shot Top 10 F' (Invitrogen) was used for subcloning the putative sulfonamide-susceptible folP gene in the Twist strain and the resistant folP gene of wild-type T. whipplei. The E. coli dhps knockout strain Bl21⌬ folP::Km r was used to study complementation and susceptibility to sulfamethoxazole. Because of the deficiency of the chromosomal DHPS enzyme, the mutant E. coli strain requires rich medium for growth, such as Luria Bertani rich medium 2XYT with 2 times the normal amount of tryptone and yeast extract, supplemented with thymidine (200 g/mL) and kanamycin (50 g/mL).
Amplification of the wild-type and mutated genes encoding putative DHPS, and techniques for cloning DNA. The wildtype sequence that encodes putative DHPS was amplified from the DNA of T. whipplei Twist, using folT1. NcoI and SacI sites were added to the 5' ends of folT1 and folT2, respectively. The primers used to amplify the mutated putative DHPS gene were folM1 (table 2). A NcoI site was added to the 5' end of folM1. The sizes of the amplified fragments (length, ϳ909 bp) were verified by electrophoresis on 1% agarose gels. The PCR products were purified using the QIAquick PCR purification kit (Qiagen) and digested with NcoI and SacI. These PCR products were then ligated into a pIVEX2.3d vector (Roche Diagnostics) previously digested by the 2 enzymes and purified by extraction from an agarose gel, using the QIAquick gel extraction kit (Qiagen).
Transformation in the E. coli One Shot Top10 F' strain. E. coli One Shot Top 10 F' was transformed using constructs that contained the mutated folp gene (plasmid pIVEX2.3dfolpM) and wild-type folp gene (plasmid pIVEX2.3dfolpNM), by heatshock transformation. LB-ampicillin agar plates were used for selection of recombinant clones. Screening of recombinant clones was performed by PCR, using a 5' primer complementary to the T7 promoter and a 3'-primer complementary to the T7 terminator of the pIVEX2.3d vector, as well as by enzymatic digestion of plasmids by SacI and NcoI. The size of the amplified and digested PCR products (1.17 kb) was visualized by electrophoresis on 1% agarose gels.
Transformation in the Bl21⌬folp mutant. The E. coli One Shot Top 10 F' recombinant clones were cultivated in Luria Bertani broth supplemented with ampicillin. This culture was used to purify plasmids (pIVEX2.3dfolpM and pIVEX2.3dfolpNM), using the QIAprep Spin Miniprep kit (Qiagen). Competent cells of the Bl21⌬folp knock-out mutant were prepared as previously described [22] . Plasmids coding for wild-type putative DHPS (pIVEX2.3dfolpNM) and mutant putative DHPS (pIVEX2. 3dfolpM) were used to transform competent Bl21⌬folp cells, by heat-shock transformation. For complementation with cloned folP genes, we used general Luria Bertani agar with kanamycin (50 g/mL) and ampicillin (100 g/mL) without the addition of thymidine in order to get good selection. Complementary plasmids will allow normal growth after overnight incubation, whereas plasmids without complementation will not permit visible growth.
Antibiotic Susceptibility Tests
Susceptibility tests were performed with discs containing 25 g of sulfamethoxazole on Mueller-Hinton plates supplemented with kanamycin (50 g/mL), ampicillin (100 g/mL), and isopropyl-␤-D-thiogalactopyranoside (0.5 mmol/L). Inoculums were fixed at 1 McFarland for standardization of the number of bacteria, and the diameter of growth inhibition around the disc of antibiotics was recorded. Minimal inhibitory concentrations of sulfamethoxazole were also determined using the Etest strip assay (AB Biodisk). Susceptibility of E. coli ATCC29522 was used as a control.
RESULTS

T. whipplei Genotyping and Culture
Genotyping analyses revealed that the strain infecting the case patient was the same at the time of the Whipple disease diagnosis and at those of the time of clinical resistance with an homology of 100% observed between the 2 highly variable genomic sequences tested (data not shown) [18] . Growth of T. whipplei on stool culture was slow, which accords with previously reported observations [17] . Twenty-three months a Sequence retrieved from the complete genome (available at: http://www.genome.jp). b ENDO 7 and ENDO 7B were isolated from the cardiac valve and blood, respectively, from a patient with endocarditis due to T. whipplei.
c Sequence used in Escherichia coli Bl21⌬folp for demonstration of sulfamethoxazole resistance. after the inoculation, T. whipplei PCR performed on the culture's supernatant was still positive. Unfortunately, at this time, the culture has been contaminated by fungi. Thus, the strain could not be established.
Identification of the Gene Encoding Putative DHPS, Sequencing of DNA from Patient Isolates, and Detection of Critical Amino Acid Mutations
At the KEGG Web site, we found a gene, which we named jmg, that encodes a trifunctional enzyme 765-766 amino acids long and combines putative DHPS with the 2 preceding enzymes in the de novo folate biosynthesis pathway, 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase and 7,8-dihydroneopterin aldolase (figure 2). Thus, putative DHPS encoded by the folP gene was found to be the first part of this trifunctional enzyme (ϳ900 nucleotides long, compared with the length of E. coli DHPS). According to these sequences (which were 100% identical) and genome maps, we designed primers (table 2) to frame the first part of the jmg gene encoding putative DHPS in order to amplify the corresponding genes in the 20 clinical isolates, as well those in isolates from the case patient's biopsy specimens. Although nucleotide substitutions in the sequences from our 20 clinical isolates did not differ from those in the portion of the jmg gene in T. whipplei strains Twist and TW08/27 that encodes putative DHPS, we found 3-5 nucleotide substitutions that led to amino acid changes in the sequence in T. whipplei recovered from the case patient (Genbank accession number EF632106) (table 1) . A 3-dimensional image of the 3 critically mutated amino acids in putative DHPS is shown in figure 3 . 
Transformation in the E. coli One Shot Top 10 F' Strain and the Bl21⌬folp Mutant
E. coli One Shot Top 10 F'. Two sequences encoding putative DHPS were used for this study: the sequence in the T. whipplei strain Twist, which is known to be susceptible to sulfamethoxazole [14] , and the mutated sequence in the T. whipplei isolate obtained from the case patient at the time of clinical resistance to trimethoprim-sulfamethoxazole (table 1) . We obtained clones on Luria Bertani-ampicillin agar plates. PCR, using the primers described above, showed a band of ϳ1000 bp for positive clones, corresponding to the correct insert. Successful cloning was verified by restriction mapping of the construct, using SacI and NcoI enzymes and subsequent analysis on an agarose gel. Bl21⌬folp mutant. Correct constructs, pIVEX2.3dfolpNM and pIVEX2.3dfolpM, were used to transform the Bl21⌬folp mutant. Correct clones were cultivated on nonrich medium (i.e., Luria Bertani medium supplemented with kanamycin, ampicillin, isopropyl-␤-D-thiogalactopyranoside, without the addition of thymidine). Bl21⌬folp transformants grew in this medium, whereas untransformed Bl21⌬folp did not grow. These results demonstrate that we were able to restore putative DHPS activity, using our heterologous system.
Antibiotic Susceptibility Tests
Susceptibility tests of Bl21⌬folp complementary to sulfamethoxazole showed that Bl21⌬folp pIVEX2.3dfolpNM, which corresponds to the wild-type sequence encoding putative DHPS, was susceptible to sulfamethoxazole, with a culture inhibition diameter of 21-22 mm, whereas Bl21⌬folp pIVEX2.3dfolpM, which corresponds to the mutated sequence encoding putative DHPS, showed a diameter of 8 -13 mm (figure 4). Minimal inhibitory concentrations of sulfamethoxazole, determined using Etest, ranged from 2 to 4 g/mL and from 8 to 12 g/mL for Bl21⌬folp pIVEX2.3dfolpNM (wild-type sequence) and Bl21⌬folp pIVEX2.3dfolpM (mutated sequence), respectively (figure 4).
DISCUSSION
Here, we report a case of trimethoprim-sulfamethoxazole failure for Whipple disease after initial improvement [4] . Five other cases of trimethoprim-sulfamethoxazole failure have previously been documented. It is difficult to evaluate the incidence of resistance to trimethoprim-sulfamethoxazole during Whipple disease. Two cases of treatment failure (one during initial treatment and one during secondary treatment) were described in a German study among 13 treatment episodes (15%), one of which involved a patient who died [4] , and treatment failure in 1 of 15 treatment episodes was reported from a French series [6] . Currently, we receive samples for diagnosis, and we recommend treatment for 20 -30 patients per year in our center. It is estimated that the incidence of Whipple disease in France is 0.5-1 cases per 10 6 inhabitants [1] . On the basis of this and information of such cases for 4 patients in 3 years from France, we estimate that 5%-20% of treatments based on classical trimethoprim-sulfamethoxazole may result in failure.
T. whipplei is very fastidious, and the rate of growth of isolates resistant to trimethoprim-sulfamethoxazole appears to be slower than isolates susceptible to these agents (unpublished data). These characteristics make it impossible to test the sulfamethoxazole susceptibility of T. whipplei. Molecular identification of the gene sequence associated with resistance might be useful for detection of putative resistance [23] .
Functional genes from T. whipplei have not been expressed before. Here, we identified and expressed the first part of the jmg gene, which encodes putative DHPS. In T. whipplei, the gene expressing putative DHPS is polycistronic and encodes a trifunctional enzyme involved in the folate biosynthesis pathway, whereas in other prokaryotes, a monocistronic gene encodes DHPS [24] . Polycistronic genes are found in several species: Streptococcus pneumoniae has a gene that encodes the bifunctional enzyme dihydroneopterin aldolase and hydroxymethyl dihydropterin pyrophosphokinase [25] , Plasmodium falciparum has one that encodes the bifunctional enzyme hydroxymethyldihydropterin pyrophosphokinase and dihydropteroate synthase [26] , and Pneumocystis jirovecii has one that encodes a trifunctional polypeptide, similar to that found for T. whipplei, consisting of dihydroneopterin aldolase, hydroxymethyldihydropterin pyrophosphokinase, and dihydropteroate synthase [27, 28] . Multifunctional enzymes are thought to have evolved by the fusion of smaller monofunctional proteins, where each enzyme activity exists as a separate functional domain as dem- Figure 4 . Minimum inhibitory concentrations of sulfamethoxazole against Escherichia coli transformed with wild-type and mutated putative DHPS sequences, determined using Etest strips (AB Biodisk). A, E. coli Bl21⌬folp pIVEX2.3dfolpNM, which corresponds to the wild-type sequence encoding putative DHPS. B, E. coli Bl21⌬folp pIVEX2.3dfolpM, which corresponds to the mutated sequence encoding putative DHPS.
onstrated in the present study. Evolution of this unique trifunctional enzyme in T. whipplei remains unknown, particularly because the degree of similarity of the complete protein sequence in T. whipplei with that of P. jirovecii and the degree of homology between the portion of the sequence encoding putative DHPS and that of E. coli DHPS are low (Ͻ40% each; data not shown). Of interest, this trifunctional gene has been cloned and expressed in both E. coli and Saccharomyces cerevisiae strains, allowing evaluation of mutations in putative DHPS that are implicated in resistance to sulfonamide [27, 29] .
In the present study, we demonstrated that the first part of the jmg gene encoding putative DHPS was the target of sulfonamides and was able to restore the folic acid pathway by complementation in E. coli. Under the same conditions, E. coli with a mutated folP gene from a patient with clinically acquired resistance was resistant to sulfamethoxazole. These mutations are significantly associated with sulfonamide resistance, and on the basis of the homology between the 3-dimensional structure of putative DHPS and that of E. coli DHPS, they are localized in highly conserved site of the enzyme [27, 30] . The change from threonine to proline at position 102 may be critical, because this amino acid, situated at the end of an ␣ helix, may have fewer constraints on the secondary structure of the protein, owing to lower local interresidue interactions mediated by hydrogen bonds in the mutated predicted protein sequence.
Our results may allow early detection of resistance to sulfonamide drugs. Single mutations in folP can rapidly result in acquired resistance, making monotherapy with sulfamethoxazole highly risky [3] . In this report, it is necessary to emphasize that, in isolates from the duodenal biopsy specimen obtained from the case patient before clinical failure, PCR detected 2 nucleotide substitutions that were not present in susceptible controls. As several attempts for gene complementation with the original sequence obtained before clinical failure were unsuccessful, the restoration of folate biosynthesis and sulfamethoxazole susceptibility with this parental sequence could not be performed. Thus, the in vitro impact of these 2 nucleotide substitutions is not known. Because these mutations were not detected in other clinical strains and because initial clinical response with trimethoprim-sulfamethoxazole was excellent, it is possible that the parental strain had a higher propensity to become more resistant after a first course of antibiotic. Further studies are needed to better understand the relationship between mutations in this region and resistance to sulfonamide compounds. Finally, the inability of our standardized culture system to establish a culture of T. whipplei from samples obtained from the case patient prevents routine susceptibility testing and detection of drug resistance. This may be linked to the resistance to sulfonamides. Indeed, several studies have demonstrated that antibiotic resistance, whether caused by target alteration or by other mechanisms, including those associated with sulfonamides, most often confers a reduction in bacterial fitness [31, 32] .
In conclusion, on the basis of these data, we recommend the avoidance of treatment by trimethoprim-sulfamethoxazole at the currently recommended dosage because it favors the appearance of mutations in the gene targeted by sulfonamide. We suggest the use of doxycycline and hydroxychloroquine for patients without neurologic involvement (i.e., patients with cerebrospinal fluid that is PCR negative for T. whipplei and/or those who lack neurologic manifestations of Whipple disease). In case of neurologic involvement, we suggest an increase in the daily sulfonamide regimen, by either increasing trimethoprimsulfamethoxazole to 4800 mg/day sulfamethoxazole or using sulfadiazine 1500 mg 4 times/day, as for the treatment of cerebral toxoplasmosis [33] , in association with doxycycline and hydroxychloroquine. a Forward primer for amplification of dhps in T. whipplei strain Twist. The restriction enzyme site NcoI is underlined. b Reverse primer for amplification of dhps in T. whipplei strain Twist and mutated dhps in a stool specimen from the case patient from whom an isolate with clinically acquired resistance was recovered. The restriction enzyme site SacI is underlined.
c Forward primer for amplification of mutated dhps in a stool specimen from the case patient from whom an isolate with clinically acquired resistance was recovered. The restriction enzyme site NcoI is underlined.
